新版國家醫保藥品目錄落地 全球首個IgA腎病對因治療藥物耐賦康(R)納入報銷
Jan 02, 2025 10:52 HKT |  |
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
Jan 02, 2025 10:52 HKT | |
|
新版国家医保药品目录落地 全球首个IgA肾病对因治疗药物耐赋康(R)纳入报销
Jan 02, 2025 10:48 HKT | |
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area
Dec 18, 2024 14:29 HKT | |
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）大灣區內地首張處方在佛山正式落地
Dec 18, 2024 14:20 HKT | |
|
云顶新耀宣布伊曲莫德（VELSIPITY(R)）大湾区内地首张处方在佛山正式落地
Dec 18, 2024 14:20 HKT | |
|
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY
Dec 17, 2024 10:58 HKT | |
|
雲頂新耀宣佈中國國家藥品監督管理局正式受理伊曲莫德（VELSIPITY(R)）
Dec 17, 2024 10:53 HKT | |
|
云顶新耀宣布中国国家药品监督管理局正式受理伊曲莫德（VELSIPITY(R)）
Dec 17, 2024 10:47 HKT | |
|
CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers
Dec 12, 2024 22:00 HKT |  |
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau
Dec 12, 2024 12:11 HKT | |
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）在中國澳門的首張處方落地
Dec 12, 2024 12:02 HKT | |
|
云顶新耀宣布伊曲莫德（VELSIPITY(R)）在中国澳门的首张处方落地
Dec 12, 2024 11:47 HKT | |
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 11, 2024 11:06 HKT | |
|
雲頂新耀：加速腎病領域創新 邁向全球生物製藥領先地位
Dec 11, 2024 11:02 HKT | |
|
云顶新耀：加速肾病领域创新 迈向全球生物制药领先地位
Dec 11, 2024 10:56 HKT | |
|
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Dec 10, 2024 20:30 HKT |  |
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Dec 04, 2024 11:08 HKT | |
|
雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果
Dec 04, 2024 10:59 HKT | |
|
云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验阶段性数据中取得积极结果
Dec 04, 2024 10:48 HKT | |
|